To assess the potential of AT1R and ETAR antibodies to serve as a biomarkers for clinical deterioration in COVID-19.
ID
Source
Brief title
Condition
- Respiratory tract infections
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The proportion of patients with an unfavourable outcome in COVID-19.
Secondary outcome
To assess the presence of ANA antibodies in the study patients, and correlate
their presence with ETAR and AT1R antibodies.
To assess the presence and titre of AT1R and ETAR antibodies at admission and
on the seventh day of admission for COVID-19
To assess cFN-EDA levels in COVID-19 patients at admission and on the seventh
day of admission for COVID-19.
Background summary
A significant proportion of COVID-19 patients admitted to hospital experience
clinical deterioration and require ICU admission. In a recently performed
cross-sectional study, it was observed that presence of AT1R and/or ETAR
antibodies are associated with an unfavourable outcome (defined as requirement
of high-flow nasal cannula, ICU admission or death during admission) in
COVID-19.
Study objective
To assess the potential of AT1R and ETAR antibodies to serve as a biomarkers
for clinical deterioration in COVID-19.
Study design
Prospective single centre, observational cohort study.
Study burden and risks
Peripheral blood will be withdrawn once, after informed consent, by means of
vena puncture during admission for COVID-19. Vena puncture can cause mild
discomfort; the puncture could be experienced as being painful, and a hematoma
could result from this procedure. There are no further risks associated with
participation. The subject will not have direct benefit from the findings in
this study, but it could be of great value for optimizing risk assessment in
the current COVID-19 pandemic.
Dr. Molewaterplein 40
Rotterdam 3015 GD
NL
Dr. Molewaterplein 40
Rotterdam 3015 GD
NL
Listed location countries
Age
Inclusion criteria
All patients presenting at the Emergency department with respiratory symptoms
and/or fever are evaluated for participation.
In order to be eligible to participate in this study, a subject must meet all
of the following criteria:
- Age >= 18 years
- Hospitalized with PCR confirmed COVID-19
- Able to sign informed-consent form
Exclusion criteria
A potential subject who meets any of the following criteria will be excluded
from participation in this study:
- the patients gives no informed consent
- Already hospitalized for >72 hours
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL75731.078.20 |